Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17,809 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oligosecretory Waldenström macroglobulinemia exhibits excellent treatment response and outcomes.
Xiong W, Yu Y, Sun C, Du J, Cai Z, Wang Z, Cao X, Yan Y, Chen J, Huang Y, Jiang Z, Wang H, Niu T, Yang G, Xue H, Li B, Huang H, Li Z, Liu Q, Li F, Bai O, Mao M, Fu R, Wang L, Li C, Chu X, Liu L, Dong Y, Wang L, Luo J, Wei Y, Cui R, Qiu L, Li J, Yi S. Xiong W, et al. Among authors: jiang z. Haematologica. 2024 Feb 1;109(2):666-670. doi: 10.3324/haematol.2023.283402. Haematologica. 2024. PMID: 37706332 Free PMC article. No abstract available.
Development and validation of a prediction model (AHC) for early identification of refractory thrombotic thrombocytopenic purpura using nationally representative data.
Gui RY, Huang QS, Cai X, Wu J, Liu HX, Liu Y, Yang LH, Zhang JY, Cheng YF, Jiang M, Mao M, Fang MY, Liu H, Wang LR, Wang Z, Zhou HB, Lan H, Jiang ZX, Shen XL, Zhang L, Fan SJ, Li Y, Wang QF, Huang XJ, Zhang XH. Gui RY, et al. Among authors: jiang m, jiang zx. Br J Haematol. 2020 Oct;191(2):269-281. doi: 10.1111/bjh.16767. Epub 2020 May 26. Br J Haematol. 2020. PMID: 32452543 Free article. Clinical Trial.
Treatment and outcome patterns of patients with Waldenström's macroglobulinemia: a large, multicenter retrospective review in China.
Cao XX, Yi SH, Jiang ZX, He JS, Yang W, Du J, Sun CY, Wu Y, Chen WM, Liu XJ, Li BZ, Li CR, Sang W, Liu QH, Chu XX, Li F, Bai O, Mao M, Fu R, Wang W, Liu LH, Wang LQ, Dong YJ, Luo J, Li ZL, Wei YQ, Zhang QK, Liu J, Ding KY, Zou L, Chen BY, Hua LM, Jing HM, He J, Wang L, Li J, Qiu LG. Cao XX, et al. Leuk Lymphoma. 2021 Nov;62(11):2657-2664. doi: 10.1080/10428194.2021.1938030. Epub 2021 Jun 9. Leuk Lymphoma. 2021. PMID: 34105439
Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China.
Liu W, Ji J, Zou D, Cao Y, Xu Y, Zhou J, Gao S, Wang F, Chen W, Du J, Zhou H, Zhou F, Shi J, Zhang X, Yang J, Jing H, Jiang Z, Liu H, Li C, Peng H, Jiang S, Wei X, He P, Liu Y, Yang H, Li Z, Huang X, Liu L, Shen L, Liu C, Song Y, Qiu L, Wang X, Ma J, Zhu J. Liu W, et al. Among authors: jiang s, jiang z. Bone Marrow Transplant. 2023 Mar;58(3):349-352. doi: 10.1038/s41409-022-01899-w. Epub 2022 Dec 17. Bone Marrow Transplant. 2023. PMID: 36528754 No abstract available.
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, Cheng P, Huang R, Yang L, Hu J, Hou M, Yao Y, Liu L, Wang Y, Wu D, Zhang L, Zheng C, Shen X, Hu Q, Liu J, Jin J, Luo J, Zeng Y, Gao S, Zhang X, Zhou X, Shi Q, Xia R, Xie X, Jiang Z, Gao L, Bai Y, Li Y, Xiong J, Li R, Zou J, Niu T, Yang R, Hu Y. Mei H, et al. Among authors: jiang z. J Hematol Oncol. 2021 Feb 25;14(1):37. doi: 10.1186/s13045-021-01047-9. J Hematol Oncol. 2021. PMID: 33632264 Free PMC article. Clinical Trial.
Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study.
Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, Cheng P, Huang R, Yang L, Hu J, Hou M, Yao Y, Liu L, Wang Y, Wu D, Zhang L, Zheng C, Shen X, Hu Q, Liu J, Jin J, Luo J, Zeng Y, Gao S, Zhang X, Zhou X, Shi Q, Xia R, Xie X, Jiang Z, Gao L, Bai Y, Li Y, Xiong J, Li R, Zou J, Niu T, Yang R, Hu Y. Mei H, et al. Among authors: jiang z. J Thromb Haemost. 2022 Mar;20(3):716-728. doi: 10.1111/jth.15602. Epub 2021 Dec 15. J Thromb Haemost. 2022. PMID: 34821020 Free article. Clinical Trial.
Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial.
Zhang Y, Zhou H, Jiang Z, Wu D, Zhuang J, Li W, Jiang Q, Wang X, Huang J, Zhu H, Yang L, Du X, Li F, Xia R, Zhang F, Hu J, Li Y, Hu Y, Liu J, Jin C, Sun K, Zhou Z, Wu L, Yu W, Jin J. Zhang Y, et al. Among authors: jiang q, jiang z. Am J Hematol. 2022 Dec;97(12):1510-1519. doi: 10.1002/ajh.26709. Epub 2022 Oct 4. Am J Hematol. 2022. PMID: 36054786 Free PMC article. Clinical Trial.
Current situation and development of hematopoietic cell transplantation centers: A nationwide survey in China.
Fan Y, Xu M, Tu Y, Hu Y, Liu Q, Zhao W, Zhang X, Sun Z, Niu T, Hu J, Li J, Liu L, Liu L, Wang S, Gao S, Lai Y, Song X, Li Z, Wang J, Jiang Z, Xu Y, Yan J, He P, Yang J, Chen J, Xu Y, Huang X, Wu D; National Clinical Research Center for Hematologic Diseases (NCRCH) at Suzhou. Fan Y, et al. Among authors: jiang z. Chin Med J (Engl). 2024 Jan 22. doi: 10.1097/CM9.0000000000002984. Online ahead of print. Chin Med J (Engl). 2024. PMID: 38251709 No abstract available.
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
Zhang Y, Zhou H, Jiang Z, Wu D, Zhuang J, Li W, Jiang Q, Wang X, Huang J, Zhu H, Yang L, Du X, Li F, Xia R, Zhang F, Hu J, Li Y, Hu Y, Liu J, Jin C, Sun K, Zhou Z, Wu L, Yin H, Suo S, Yu W, Jin J. Zhang Y, et al. Among authors: jiang q, jiang z. Am J Hematol. 2024 Apr;99(4):774-779. doi: 10.1002/ajh.27245. Epub 2024 Feb 11. Am J Hematol. 2024. PMID: 38343062 Clinical Trial.
17,809 results
You have reached the last available page of results. Please see the User Guide for more information.